Akers Biosciences Announces Q3 2018 Earnings Sales of Flagship PIFA Heparin PF/4 Rapid Assay Products Up 16% over Q3 2017; Company Continuing to Evaluate Strategic Alternatives to Maximize Shareholder Value THOROFARE, N.J., Nov. 15, 2018 ...

Akers Biosciences Announces Intention to Explore Strategic Alternatives to Maximize Shareholder Value Announces 1:8 Reverse Stock Split THOROFARE, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid...

Akers Biosciences Announces a Change to the Board of Directors THOROFARE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces...

Akers Biosciences Withdraws FDA 510(k) Submission for PIFA Chlamydia Rapid Assay Pending Further Evaluation THOROFARE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces...

Akers Biosciences Announces Conference Call to Discuss Fiscal Year 2017 Earnings THOROFARE, N.J, March 15, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, will...